Principles of Immunotherapy

Joscelyn, Jennifer; Ochoa‐Repáraz, Javier; Kasper, Lloyd H.

doi:10.1007/978-3-030-24436-1_2

Cited by 2 publications

(2 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Wei et al [ 14 ], diversity in B cell responses plays a crucial role in shaping the effectiveness of immune responses in B cell malignancies. We acquired at least 5000 B cells (CD19 + events) ( Figure 1 A) and defined memory B cells as CD19 + CD27 + events [ 15 , 16 ] ( Figure 1 B), activated B cells as CD19 + CD27 − CD38 + events, and activated memory B cells [ 16 ] as CD19 + CD27 + CD38 + events ( Figure 1 C). Details can be found in the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) document ( Supplementary Table S2 ).…”

Section: Methodsmentioning

confidence: 99%

B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia

Ntsethe,

Mkhwanazi,

Dludla

et al. 2024

CIMB

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is characterized by dysfunctional B cells. Immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1) are upregulated in patients with CLL and may correlate with prognostic markers such as beta-2 microglobulin (B2M). The aim of this study was to evaluate the levels of immune checkpoints on B cell subsets and to further correlate them with B2M levels in patients with CLL. We recruited 21 patients with CLL and 12 controls. B cell subsets and the levels of immune checkpoint expression were determined using conventional multi-color flow cytometry. Basal levels of B2M in patients with CLL were measured using an enzyme-linked immunosorbent assay. Patients with CLL had increased levels of activated B cells when compared to the control group, p < 0.001. The expression of PD-1 and CTLA-4 were increased on activated B cells and memory B cells, p < 0.05. There were no associations between B2M levels and the measured immune checkpoints on B cell subsets, after adjusting for sex and age. In our cohort, the patients with CLL expressed elevated levels of PD-1 and CTLA-4 immune checkpoints on activated and memory B cell subsets. However, there was no correlation between these immune checkpoint expressions and B2M levels.

show abstract

Section: Methodsmentioning

confidence: 99%

B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia

Ntsethe,

Mkhwanazi,

Dludla

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

“…According to Wei et al [14], diversity in B cell responses plays a crucial role in shaping the effectiveness of immune responses in B cell malignancies. We acquired at least 5000 B cells (CD19 + events) (Figure 1A) and defined memory B cells as CD19 + CD27 + events [15,16] (Figure 1B), activated B cells as CD19 + CD27 − CD38 + events, and activated memory B cells [16] as CD19 + CD27 + CD38 + events (Figure 1C). Details can be found in the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) document (Supplementary Table S2).…”

Section: Measurements Of B Cell Subsetsmentioning

confidence: 99%

B Cell Subsets and Immune Checkpoint Expression in Patients With Chronic Lymphocytic Leukaemia

Ntsethe,

Mkhwanazi,

Dludla

et al. 2024

Preprint

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is characterized by dysfunctional B cells. Immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and programmed death-1 (PD-1) are upregulated in patients with CLL and may correlate with prognostic markers such as beta-2 microglobulin (B2M). The aim of this study was to evaluate the levels of immune checkpoints on B-cell subsets and to further correlate them with B2M levels in patients with CLL. We recruited 21 patients with CLL and 12 controls. B cell subsets and the levels of immune checkpoint expression were determined using conventional multi-color flowcytometry. Basal levels of B2M in patients with CLL were measured using an Enzyme-linked immunosorbent assay. Patients with CLL had increased levels of activated B cells when compared to the control group, p< 0.001. The expression of PD-1 and CTLA-4 were increased on activated B cells and memory B cells, p< 0.05. There were no associations between B2M levels and the measured immune checkpoints on B cell subsets, after adjusting for sex and age. African patients with CLL express elevated levels of PD-1 and CTLA-4 immune checkpoints on activated and memory B cell subsets. However, there is no correlation between these immune checkpoint expressions and B2M levels.

show abstract

Principles of Immunotherapy

Cited by 2 publications

References 140 publications

B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia

B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia

B Cell Subsets and Immune Checkpoint Expression in Patients With Chronic Lymphocytic Leukaemia

Contact Info

Product

Resources

About